Article

AKR1C mediates the acquired resistance to T-Dxd in a HER-2 positive gastric cancer line

2024-12-12

Abstract excerpt

Trastuzumab deruxtecan (T-Dxd), an anti-HER2 antibody–drug conjugate, has significantly enhanced clinical outcomes for patients as a HER2-directed therapy compared to previous standards of care. However, acquired resistance is always a concern, necessitating further investigation into the underlying resistance mechanism. In this study, we successfully established T-Dxd-resistant cell line (N87-R) by exposing HER2-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 22a20f72-b371-5169-84fa-b8f1cd0097ea
DOI: 10.1101/2024.12.11.627923

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AKR1C mediates the acquired resistance to T-Dxd in a HER-2 positive gastric cancer lineDOI 10.1101/2024.12.11.627923Read

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancerSemantic proximity Read

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugsSemantic proximity Read

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancerSemantic proximity Read

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerSemantic proximity Read

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistanceSemantic proximity Read

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read

UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.Semantic proximity Read

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.Semantic proximity Read

HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.Semantic proximity Read

Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise UsSemantic proximity Read

Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs.Semantic proximity Read